Is GHK-Cu FDA Approved? What the Upcoming FDA Review Actually Covers

Written by the NuLab Editorial Team · Published July 31, 2026 · Last reviewed July 31, 2026

GHK-Cu has moved from cosmetic-chemistry circles into beauty feeds and peptide discussions. Now an upcoming FDA advisory meeting is adding a second kind of attention—and considerable room for confusion.

Editorial scope: This article reports on cosmetic regulation, pharmacy-compounding policy and published human research. It does not recommend GHK-Cu for any medical or cosmetic use. It does not provide dosing, preparation or administration instructions. NuLab products are intended solely for laboratory research and are not for human or animal consumption.

Quick answer: No. GHK-Cu is not an FDA-approved drug. FDA has announced that its Pharmacy Compounding Advisory Committee will consider GHK-Cu, except for injectable routes of administration, for possible inclusion on the Section 503A Bulks List at a meeting to be held before the end of February 2027. That proceeding is a pharmacy-compounding review—not a drug-approval application. The committee's recommendation will be advisory, compounded drugs remain unapproved, and the announced review does not cover injectable GHK-Cu.

Status as of July 31, 2026: The meeting date and location have not been announced. FDA has identified GHK-Cu as an agenda item, but the agency has not yet published its GHK-Cu briefing document, the precise uses it will evaluate or the questions it will put to the committee.

In this report

• Why GHK-Cu is receiving new attention
• What FDA has actually announced
• Cosmetics, compounded drugs and injectable products are different categories
• FDA approval versus a 503A Bulks List review
• What the committee is expected to consider
• What human evidence exists—and where it falls short
• Why copper coordination and product form matter
• What the upcoming meeting can and cannot establish
• GHK-Cu FDA review FAQs

Why GHK-Cu is receiving new attention

GHK-Cu is not a new molecule. It is a copper complex of the three-amino-acid peptide glycine-histidine-lysine, commonly shortened to GHK. The complex has appeared in skin biology, wound-repair and cosmetic research for decades.

What is new is the size and variety of the audience encountering it.

In February 2026, TIME included GHK-Cu in its reporting on unapproved peptide injections moving from niche bodybuilding and biohacking communities into mainstream social-media culture. In July, Marie Claire UK described GHK-Cu as a copper peptide “taking over” skincare feeds and discussed serums, creams and injectable products in the same feature.

That convergence has created a search problem as much as a science problem. A reader who searches for “GHK-Cu” may be shown:

• a cosmetic serum listing Copper Tripeptide-1;
• a paper about GHK-Cu in cultured cells;
• a compounded topical drug;
• a laboratory research vial;
• an injectable product promoted online; or
• an FDA announcement about a future advisory-committee meeting.

Those results may use the same short name, but they do not describe products with the same intended use, regulatory status, formulation, evidence or risk profile.

The FDA announcement is therefore important partly because it forces a distinction that social-media posts often erase: the agency's announced review excludes injectable routes.

What FDA has actually announced

FDA says it will host a meeting of the Pharmacy Compounding Advisory Committee, usually called PCAC, before the end of February 2027. The agenda lists five bulk drug substances:

• Cathelicidin (LL-37);
• GHK-Cu;
• Dihexa acetate;
• Melanotan II; and
• pegylated mechano growth factor, or PEG-MGF.

The committee will discuss whether these substances should be included on the 503A Bulks List, which is part of the federal framework for certain patient-specific compounded drugs.

The route limitation appears in a separate FDA status document. The agency lists “GHK-Cu (except for injectable routes of administration)” in Category 1, its category for nominated substances under evaluation.

The route language has an unusual recent history:

1. FDA removed GHK-Cu from Category 1 on April 22, 2026, after the nominations appeared to have been withdrawn.
2. On May 5, one nominator clarified that it intended to withdraw only the nomination for injectable administration.
3. FDA then restored the non-injectable GHK-Cu nomination to Category 1 and announced the forthcoming committee review.

That sequence does not mean FDA first prohibited and then approved GHK-Cu. It records the status of a nomination while the agency evaluates whether a bulk substance should appear on a compounding list.

Category 1 is also not a safety grade. It means FDA has sufficient nomination information to evaluate the substance and has not placed it in another interim category. Under FDA's current guidance, some Category 1 compounding may fall within an interim enforcement policy when all of the policy's conditions are met. That is different from a finding that a substance is safe, effective or FDA approved.

Cosmetics, compounded drugs and injectable products are different categories

The easiest way to misunderstand the upcoming meeting is to treat every product called GHK-Cu as one regulatory object. It is not.

Product context	What defines it	What FDA approval means
Cosmetic containing Copper Tripeptide-1	Intended to cleanse, beautify, promote attractiveness or alter appearance	FDA generally does not preapprove cosmetic products or ingredients, except color additives
Product marketed to treat disease or affect body structure or function	Intended use makes it a drug under federal law, even if it is applied to the skin	The drug generally needs an approved application or a lawful over-the-counter monograph pathway unless an exemption applies
Patient-specific compounded drug under Section 503A	Prepared by an eligible pharmacist or physician under statutory conditions for an identified patient	Compounded drugs are not FDA approved and do not receive FDA premarket review for safety, effectiveness and quality
Injectable GHK-Cu promoted online	Route and human-use claims place it outside an ordinary cosmetic context	The announced GHK-Cu PCAC review expressly excludes injectable routes; it does not validate these products
Laboratory research material	Intended for controlled laboratory research, not personal use	It is not interchangeable with a cosmetic, compounded prescription or FDA-approved drug

A cosmetic ingredient is not an FDA-approved drug

In U.S. law, classification depends heavily on intended use. A product sold to moisturize skin or improve appearance may be a cosmetic. A product promoted to heal wounds, restore hair growth, regenerate tissue or treat a disease may meet the legal definition of a drug, even if it comes in a serum or cream.

FDA does not maintain a list of approved cosmetic claims, and it generally does not approve cosmetic ingredients before they reach the market. An independent Cosmetic Ingredient Review panel has assessed Copper Tripeptide-1 and related ingredients as safe under the cosmetic uses and concentrations it reviewed. That assessment is relevant to those specified cosmetic conditions, but it is not FDA approval, and it cannot be extended to concentrated raw material, compounded drugs or injection.

Topical does not automatically mean cosmetic

Route alone does not determine the category. A product applied to the skin can be a cosmetic, a drug or both, depending on its ingredients, claims and intended use.

That point matters for the coming meeting. FDA has said only that the GHK-Cu nomination excludes injectable routes. The agency has not yet published meeting materials identifying every non-injectable route, formulation and proposed use it will evaluate. It would be premature to describe the proceeding simply as a “skincare review.”

Injectable GHK-Cu is outside the announced nomination

The clearest current fact is the exclusion. The nominator withdrew injectable administration, and FDA's Category 1 entry now excludes it.

No future vote on the non-injectable nomination should be presented as evidence that injectable GHK-Cu has passed FDA review. It will not have done so.

FDA approval versus a 503A Bulks List review

These processes answer different questions.

Drug approval asks about a defined finished product

An FDA drug-approval review ordinarily examines a specific product, formulation, manufacturing process, route, dose, labeling and intended use. The sponsor must submit evidence supporting quality, safety and effectiveness.

If FDA approves the application, the approval applies to that defined product and its labeling. It is not a general endorsement of every material that shares an ingredient name.

The 503A process asks whether a bulk substance may be used in qualifying compounding

Section 503A allows certain patient-specific compounded drugs to qualify for exemptions from parts of federal drug law when all statutory conditions are met.

When a bulk drug substance lacks an applicable United States Pharmacopeia or National Formulary monograph and is not a component of an FDA-approved drug, it generally must appear on the 503A Bulks List for this pathway to be available. The bulk material must also meet other conditions, including being accompanied by a valid certificate of analysis and being manufactured by an FDA-registered establishment.

Adding a substance to that list does not approve a drug made from it. FDA states plainly that compounded drugs are not FDA approved and do not undergo the same premarket evaluation as approved products.

For a recent example of how advisory recommendations fit into this longer process, read FDA Panel Backed Six Peptides for 503A Compounding. What Happens Next?.

What the committee is expected to consider

FDA has not released its GHK-Cu briefing document or final voting questions. The agency says those materials should be available no later than two business days before the meeting.

Under the framework FDA established for the 503A Bulks List, the review is expected to address four broad criteria.

1. Can the substance be physically and chemically characterized?

The committee may consider whether “GHK-Cu” identifies a sufficiently defined bulk substance and whether its relevant forms can be consistently made and tested.

For a copper-binding peptide, that is not merely a naming exercise. GHK without copper, a 1:1 GHK-copper complex, a bis-peptide copper complex, an acetate form and a finished formulation are not automatically the same chemical material.

2. What safety issues arise in compounded drug products?

Safety depends on more than the ingredient name. Route, concentration, formulation, impurities, sterility requirements, degradation products, patient population and duration of exposure can all change the risk question.

Because injection has been removed from the nomination, evidence about an injectable product should not be blended into the committee's non-injectable evaluation—or used afterward to imply that injection was endorsed.

3. What evidence supports or fails to support effectiveness?

FDA can examine laboratory findings, animal studies, human trials and the relevance of each study to the particular compounded use being proposed.

A plausible molecular mechanism is not the same as a demonstrated clinical effect. A favorable study of one topical gel also cannot establish effectiveness for every cream, serum, oral preparation or other non-injectable form.

4. What is the history of use in compounding?

The agency also considers how long and how widely the substance has been used in compounded drug products, including the routes and uses for which it has actually been compounded.

Historical use can inform the review, but it does not replace controlled evidence. Popularity and longevity are not proof of safety or effectiveness.

The committee will discuss these issues and make a nonbinding recommendation. FDA will then consider the full record. Formal inclusion on the list requires further agency action through the applicable regulatory process.

What human evidence exists—and where it falls short

GHK-Cu has more human topical research than many peptides promoted online. That statement needs two immediate qualifications: much of the literature is old or product-specific, and topical evidence cannot be transferred to injectable use.

Older wound research reported a favorable result

A 1994 multicenter, randomized, evaluator-blinded, placebo-controlled study examined a GHK-Cu gel in people with diabetic neuropathic foot ulcers. All participants also received standardized wound care. The published abstract reported greater median closure among plantar ulcers treated with the GHK-Cu gel and a lower infection rate than with vehicle.

This is genuine human evidence, but its scope is narrow. It concerned one topical gel, one clinical setting and a wound-care protocol that included debridement, pressure-relieving footwear and patient education. It does not establish a general beauty benefit, and it says nothing reliable about injection.

A small post-laser study did not show objective improvement

In 2006, researchers randomized people receiving carbon-dioxide laser resurfacing to post-treatment regimens with or without GHK-Cu. Only 13 participants completed the study.

Computer analysis and blinded evaluators found no statistically significant difference in the resolution of redness. Objective evaluation also found no between-group improvement in wrinkles or overall skin quality. Participants using GHK-Cu reported higher satisfaction with skin quality, but that subjective result did not match the objective assessments.

The study is useful precisely because it was not a uniformly positive result. It shows why a credible evidence review must report endpoints that failed as well as those that succeeded.

Frequently cited cosmetic studies are difficult to audit fully

Reviews often describe short studies in women with photodamaged skin that reported improvements in fine lines, skin density, firmness or appearance after use of GHK-Cu creams. Some of the most frequently repeated claims trace to conference presentations or limited reports rather than large, easily audited, peer-reviewed trials with modern reporting.

That does not make every reported result false. It does limit confidence in the size and reliability of the effect. Small samples, short follow-up, formulation-specific results, incomplete access to methods and possible commercial involvement all matter when judging cosmetic evidence.

A current Phase 2 topical study has no results yet

ClinicalTrials.gov lists a randomized, double-blind Phase 2 study of a topical GHK-Cu gel for standardized skin wounds in 60 healthy adults. The trial began in February 2026 and is recruiting. Its primary completion is estimated for February 2027, and no results have been posted.

Registration is a sign that a controlled study is planned or underway. It is not evidence that the treatment works. The result will remain unknown until the trial is completed, analyzed and reported.

Injectable human evidence remains the major gap

The sources reviewed for this article did not identify a completed controlled clinical trial establishing the safety and effectiveness of injectable GHK-Cu for beauty, longevity or hair-growth claims.

That absence cannot be repaired by citing topical cosmetic studies, cell experiments or animal models. Route changes exposure. It can alter concentration, distribution, metabolism, immune risk and the consequences of impurities or contamination.

The current evidence is therefore best summarized this way:

• there is biological and preclinical interest;
• there is limited, mixed and formulation-specific human topical evidence;
• a new controlled topical study is underway; and
• the evidence reviewed does not validate injectable use.

Why copper coordination and product form matter

GHK-Cu is often described as if it were one fixed blue molecule. The chemistry is more conditional.

GHK is the tripeptide glycine-histidine-lysine. Several nitrogen atoms in the peptide coordinate a copper(II) ion. The dominant complex can depend on pH, copper-to-peptide ratio, concentration, counterions, competing ligands and whether the material is examined in a crystal, a dry powder or a solution.

Some databases use several of the following names as synonyms, while other names describe genuinely different species. In every case, the label alone is not enough to prove that two test articles are identical:

• GHK;
• GHK-Cu;
• Copper Tripeptide-1;
• prezatide copper;
• prezatide copper acetate;
• bis(tripeptide-1) copper acetate; and
• a finished product that includes one of those names among many ingredients.

For a deeper explanation, see GHK-Cu Molecular Structure: How a Three-Amino-Acid Peptide Binds Copper.

Formulation can change what reaches the test system

A finished cream or gel contains more than the named peptide. Its pH, water content, stabilizers, preservatives, packaging and other ingredients can affect the form and stability of the copper complex.

GHK-Cu is also hydrophilic, and intact skin is an effective barrier. A study using excised human skin found that penetration depended on the skin layer and experimental preparation. That laboratory result helps explain why delivery cannot be inferred from an ingredient list alone, but it does not provide instructions for altering the skin barrier or establish a clinical benefit.

Identity records need to match the exact form

An analytical report should define what was actually tested. A chromatographic purity percentage does not, by itself, establish copper coordination, copper content, sterility, potency in a finished formulation or suitability for a particular route.

Strong documentation connects the exact molecular form and batch to appropriate identity, purity and, when relevant, copper-specific testing. Read why batch numbers and lot-specific certificates of analysis matter.

What the upcoming meeting can and cannot establish

The forthcoming PCAC meeting will be worth following. It may provide the most detailed public FDA review of non-injectable GHK-Cu to date.

What it can do:

• make FDA's chemistry, safety, effectiveness and historical-use analysis public;
• identify the non-injectable forms and proposed uses the agency evaluated;
• surface disagreements among reviewers, clinicians, compounders and committee members;
• produce a public advisory recommendation; and
• inform FDA's later decision about the 503A Bulks List.

What it cannot do on the day of the meeting:

• approve GHK-Cu as a drug;
• approve a cosmetic ingredient or skincare product;
• establish that all GHK-Cu products are equivalent;
• validate injectable GHK-Cu, which is excluded from the nomination;
• prove that a commercially available research vial is appropriate for personal use; or
• replace the additional FDA action required to amend the 503A Bulks List.

Those limits should remain in every headline and update about the meeting. “FDA reviews GHK-Cu” is accurate only when the article immediately explains which route, which regulatory pathway and which question FDA is reviewing.

GHK-Cu FDA review FAQs

Is GHK-Cu FDA approved?

No. GHK-Cu is not an FDA-approved drug. FDA plans to review a non-injectable GHK-Cu nomination for possible inclusion on the 503A Bulks List, which is a separate compounding process.

When will FDA review GHK-Cu?

FDA says the Pharmacy Compounding Advisory Committee meeting will occur before the end of February 2027. As of July 31, 2026, the agency has not announced the exact date or location.

Is FDA reviewing injectable GHK-Cu?

No. FDA's current Category 1 entry is “GHK-Cu (except for injectable routes of administration).” The nominator clarified in May 2026 that the injectable nomination was withdrawn.

Does Category 1 mean FDA considers GHK-Cu safe?

No. Category 1 means the substance was nominated with sufficient information for FDA to evaluate it and remains under review within an interim policy framework. It is not an approval, safety rating or effectiveness finding.

Is Copper Tripeptide-1 FDA approved for cosmetics?

FDA generally does not preapprove cosmetic ingredients, other than color additives. Copper Tripeptide-1 appears in cosmetics, but its presence in a cosmetic product should not be described as FDA approval.

Does an NDC, DailyMed listing or FDA UNII prove approval?

No. FDA states that registration, listing and substance identifiers do not themselves establish approval. Its substance database specifically warns that the availability of a UNII does not imply regulatory review or approval.

Are compounded GHK-Cu products FDA approved?

No. Compounded drugs are not FDA approved. Inclusion of a bulk substance on the 503A Bulks List can help a qualifying compounded drug meet one statutory condition, but FDA does not conduct the same premarket review of the finished compounded product.

Do topical GHK-Cu studies prove injectable GHK-Cu works?

No. Evidence from a topical cream or gel cannot be transferred to injection. Route, formulation, exposure and risk are materially different.

What should readers watch for next?

The next important documents will be the Federal Register meeting notice, FDA's GHK-Cu briefing materials, the meeting's precise questions, the committee vote and any later proposed or final rule concerning the 503A Bulks List.

The bottom line

GHK-Cu is attracting two kinds of attention at once: mainstream beauty interest and federal compounding scrutiny.

The overlap makes careful language essential. Copper Tripeptide-1 can appear in cosmetics without being an FDA-approved drug. A topical or other non-injectable compounded product is not the same as a cosmetic, and compounded drugs are not FDA approved. Injectable GHK-Cu is a separate issue—and it is expressly outside the nomination FDA has announced for the coming meeting.

The human evidence is neither empty nor definitive. Older topical studies offer some encouraging findings, one small controlled study found no objective advantage on its main measures, and a new Phase 2 topical study is underway without results. None of that establishes injectable safety or effectiveness.

The most accurate headline today is therefore a narrow one: FDA will review non-injectable GHK-Cu for possible inclusion on a pharmacy-compounding list before the end of February 2027. GHK-Cu is not FDA approved, and the meeting will not decide the status of injectable use.

References

• U.S. Food and Drug Administration, Meeting of the Pharmacy Compounding Advisory Committee.
• U.S. Food and Drug Administration, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, updated May 14, 2026.
• U.S. Food and Drug Administration, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.
• U.S. Food and Drug Administration, Understanding the Risks of Compounded Drugs.
• U.S. Food and Drug Administration, Is It a Cosmetic, a Drug, or Both?.
• U.S. Food and Drug Administration, Cosmetics Labeling Claims.
• U.S. Food and Drug Administration, Is It Really “FDA Approved”?.
• U.S. Food and Drug Administration, Prezatide Copper substance record.
• Mulder GD, Patt LM, Sanders L, et al., Enhanced Healing of Ulcers in Patients With Diabetes by Topical Treatment With Glycyl-L-Histidyl-L-Lysine Copper, Wound Repair and Regeneration 2, 259-269 (1994).
• Miller TR, Wagner JD, Baack BR, Eisbach KJ, Effects of Topical Copper Tripeptide Complex on CO2 Laser-Resurfaced Skin, Archives of Facial Plastic Surgery 8, 252-259 (2006).
• ClinicalTrials.gov, Topical GHK-Cu Gel for Acute Skin Wound Healing, NCT07437586.
• Badenhorst T, Svirskis D, Wu Z, Human Skin Penetration of a Copper Tripeptide In Vitro as a Function of Skin Layer, Inflammation and Allergy Drug Targets 10, 269-279 (2011).
• Johnson W Jr, Bergfeld WF, Belsito DV, et al., Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics, International Journal of Toxicology 37, 90S-102S (2018).
• Mosbergen D, What to Know About the “Anti-Aging” Peptide Shots Flooding Social Media, TIME (February 24, 2026).
• Ollennu A, Meet GHK-Cu, the Copper Peptide Taking Over Your Skincare Feed, Marie Claire UK (July 8, 2026).

This article provides regulatory and scientific reporting, not medical, cosmetic-use, legal or purchasing advice. NuLab products are intended strictly for laboratory research and are not for human or animal consumption.